$1.27
3.79% yesterday
Nasdaq, Aug 12, 10:00 pm CET

MaxCyte Inc Stock News

Neutral
Seeking Alpha
6 days ago
MaxCyte, Inc. (NASDAQ:MXCT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Douglas J. Swirsky - Chief Financial Officer Maher Masoud - President, CEO & Executive Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Hannah Webb Hefley - Stephens Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.
Neutral
The Motley Fool
6 days ago
MaxCyte (MXCT) Q2 Revenue Drops 18%
Neutral
GlobeNewsWire
9 days ago
MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs
Neutral
GlobeNewsWire
13 days ago
MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies MaxCyte's Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca's TCR-T cell therapies
Neutral
GlobeNewsWire
about one month ago
ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the second quarter 2025 after the U.S. market close on Wednesday, August 6...
Neutral
Business Wire
about one month ago
TOKYO--(BUSINESS WIRE)--The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo, hereafter referred to as "PHCHD") announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform(*1) in Japan. I...
Neutral
GlobeNewsWire
2 months ago
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines
Neutral
Seeking Alpha
3 months ago
MaxCyte, Inc. (NASDAQ:MXCT ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Eric Abdel - IR Maher Masoud - President and CEO Doug Swirsky - CFO Conference Call Participants Matt Larew - William Blair Julie Simmonds - Panmure Liberum Mark Massaro - BTIG Chad Wiatrowski - TD Cowen Dan Arias - Stifel Operator Good day and thank you for standing by. Welcome to the MaxC...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today